ICI treatment may restore both humoral immune responses and cytotoxic T cell activity against tumor neoantigens mediated by Tfh by elevating interleukin-21 (IL-21) secretion to B cells and CD8+ T cells, respectively (53). Here, CD8A is linked to neoplasm.